Novo Nordisk study sheds light on haemophilia treatment patterns

Novo Nordisk has announced data from a new survey that aims to help broaden understanding and improve outcomes for haemophilia patients worldwide.

The Haemophilia Experiences, Results and Opportunities (HERO) study – which was based on responses from 515 adult patients in eight countries – showed that bleed frequency and treatment regimen choice impacted the use of healthcare resources and comprehensive care services among sufferers.

Those who were treated with prophylaxis were shown to be likely to visit a comprehensive haemophilia treatment centre more frequently than those using intermittent on-demand treatment.

Prophylaxis patients also reported more frequent involvement of haemophilia nurses and social workers in the management of their disease compared with patients treated on-demand, while those with more frequent bleeding were less likely to engage in higher-risk physical activities.

Eddie Williams, corporate vice-president for biopharmaceuticals at Novo Nordisk, said: "The Hero initiative underscores Novo Nordisk's commitment to the haemophilia community and we look forward to sharing new data as it becomes available."

In May 2013, the firm reported positive data from Paradigm 2, a study that underlined the benefits of its investigational haemophilia B therapy N9-GP.